CXCL12 and cervical carcinoma: The results provide a strong rationale for future clinical trials of RTCT and plerixafor or another CXCL12/CXCR4 inhibitor aimed at improving the efficacy of frontline curative therapy for patients with cervical cancer and possibly other malignancies.